Overview

A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia

Status:
Completed
Trial end date:
2008-08-19
Target enrollment:
0
Participant gender:
All
Summary
To evaluate the safety of the long-term use of pregabalin.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Pregabalin
Criteria
Inclusion Criteria:

- Patients who completed the 13-week treatment of postherpetic neuralgia in Study
A0081120.

- Patients must be able to understand and cooperate with study procedures and have
signed a written informed consent prior to entering the study.

Exclusion Criteria:

- Patients who experienced serious adverse events in the preceding study (A0081120) that
were determined by the investigator or the study sponsor to be causally related to the
study medication.

- Patients exhibiting treatment non-compliance in the preceding study (A0081120)